BioSpace News Archive

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced it was awarded $4.7 million from the U.S. Army Medical Research & Development Command to fund its Phase 1/2 clinical trial of T-COVID, an investigational intranasal immune modulator for the treatment of outpatients with early COVID-19.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that due to faster-than-expected enrollment, the Company anticipates topline Phase 3 RELIEF results in the fourth quarter of 2020, rather than the first quarter of 2021 as previously guided.

Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML

Aprea Therapeutics Inc., a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, announced the appointments of Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to its Board of Directors.

Alkermes plc announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on July 1, 2020.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced that the U.S. FDA has issued a Complete Response Letter regarding the New Drug Application for obeticholic acid for the treatment of fibrosis due to nonalcoholic steatohepatitis.

Cancer Access Partnership is expected to result in a 59 percent savings on procured cancer medicines

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, announced that management will participate in the following upcoming virtual investor conferences

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2020 financial results will be reported after the market closes on Monday, August 10. Management will host a conference call at 5:00 p.m. Eastern Time on Au

Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD IND filing on track for mid-year and phase 1 clinical trial expected third-quarter 2020 WALTHAM, Mass., June 29, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a presentation highlightin